Solid third quarter 2019 performance with strong balance sheet for continued R&D growth First nine month financial results: Group revenues of 752.5 million Operating profit of 393.0 million Net profit of 265.3 million Ca

Solid third quarter 2019 performance with strong balance sheet for continued R&D growth

Webcast presentation tomorrow, 25 October 2019, at 14.00 CET/8 AM ET, www.glpg.com, +32 2 404 0659, code 6653712

Mechelen, Belgium; 24 October 2019, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) announces its unaudited Q3

results, which are further detailed in its Q3 2019 report available on the Galapagos website, www.glpg.com.

There is no question that the third

quarter of 2019 was defined by the unique and landmark deal with our long-time collaboration partner Gilead, announced mid-July. This 10-year research collaboration is

about maximizing innovation based on the identification and development of new mode of action medicines. Thanks to the upfront payment of $3.95 billion and a $1.1 billion equity investment by Gilead, this deal gives us the financial

strength and the independence to greatly expand our research engine and build a broader pipeline of new mode of action medicines. Gilead will have option rights on our programs outside of Europe, and as part of the agreement, they have

already executed that right for our late-stage IPF compound, GLPG1690. We will benefit greatly from Gilead s science expertise and infrastructure, said Onno van de Stolpe, CEO of Galapagos. Thanks to the progress made with

filgotinib this past quarter, we and Gilead are on track for potential new drug approvals as of the second half of 2020, and we are very excited by the prospect of bringing filgotinib as a new treatment option to RA patients.

Bart Filius, COO and CFO added, Following the upfront payment of $3.95 billion and a $1.1 billion equity investment received in the Gilead

transaction, we have an exceptionally strong balance sheet. As we continue to expand our organization to support our broad pipeline and build a commercial organization for potential launch of filgotinib in Europe next year, our financial guidance

for full year 2019 operational cash burn1 between 320 and 340 million is unchanged, excluding the impact from our new collaboration agreement with Gilead.

Following on regulatory submissions in

Europe and Japan, Gilead remains on track to submit filgotinib for approval in RA the US before year-end.

We will continue recruitment in our proprietary ISABELA, NOVESA and PINTA trials, and plan to provide an

update on recruitment timelines for the ISABELA program in H2 2019. Together with our collaboration partner Servier, we continue towards completion of the ROCCELLA trial in osteoarthritis, on track for topline results in the second half of next

year. For MOR106, together with our collaboration partners MorphoSys and Novartis, we continue executing the Phase 1 and 2 trials currently ongoing.

continue to execute on our Toledo program in order to deliver Phase 1 results and plan to start several Phase 2a trials in 2020.

quarter report 2019 (unaudited)

( millions, except basic & diluted gain / loss (-) per share)

Revenues and other income

Our revenues and other income for the first nine months of 2019 amounted to 752.5 million. The impact of the Gilead collaboration on our revenues is

596.4 million, which is related to (i) the GLPG1690 program ( 667.0 million) and (ii) the access and option rights to our drug discovery platform ( 23.9 million), offset by (iii) a negative impact on filgotinib

revenue recognition when compared to the original filgotinib agreement (- 94.0 million).

Primarily as a result of the upfront received from Gilead,

on 30 September 2019 our deferred income balance includes 2.3 billion allocated to our drug discovery platform that will be recognized linearly over 10 years, and 0.80 billion allocated to filgotinib (2015 filgotinib

contract and recent revised collaboration combined) that will be recognized over a period of 4 to 5 years.

We realized a net profit of 265.3 million for the first nine months of 2019, compared to a net loss of 44.2 million for the first nine

We reported an operating profit amounting to 393.0 million for the first nine months of 2019, compared to an operating loss of

53.5 million for the first nine months of 2018.

Our R&D expenditure in the first nine months of 2019 amounted to 298.2 million, compared to

231.8 million for the first nine months of 2018. This planned increase was mainly due to an increase of 29.1 million in subcontracting costs primarily related to our IPF program, filgotinib and other programs. Furthermore,

personnel costs increased explained by a planned headcount increase and higher costs related to bonuses and the warrant plans as a result of the increase in the Galapagos share price. These factors also contributed to the increase in our G&A and

S&M expenses, which were 61.2 million in the first nine months of 2019, compared to 26.8 million in the first nine months of 2018.

We reported a non-cash fair value loss from the re-measurement of a derivative

financial instrument triggered by the share subscription agreement with Gilead between signing and closing of the agreement amounting to 142.3 million. Such amount reflects the increase in the Galapagos share price between signing and

closing of the Gilead agreement.

Net other financial loss in the first nine months of 2019 amounted to 2.0 million, compared to net other

financial income of 9.0 million for the first nine months of 2018, which was primarily attributable to 34.9 million realized exchange loss on the U.S. dollars upfront payment from Gilead, which was partly compensated by a

32.4 million of unrealized exchange gain on our cash position in U.S. dollars (compared to 6.6 million of unrealized exchange gain on our cash position in U.S. dollars in the first nine months of 2018).

We reported a tax income amounting to 16.7 million primarily from the recognition of deferred tax assets as a consequence of the deal with Gilead.

Third quarter report 2019

report for the first nine months ended September 2019, including new accounting policies as a result of recent transactions and details of the unaudited consolidated results, is accessible via www.glpg.com/financial-reports.

Results of special and extraordinary shareholders meetings

Following the collaboration with Gilead Sciences, Inc., Gilead Biopharmaceutics Ireland UC, and Gilead Therapeutics A1 Unlimited Company announced on

14 July 2019, Galapagos held special and extraordinary shareholders meetings on Tuesday 22 October 2019.

At these meetings, all proposed

resolutions were approved, including the appointment of Mr. Daniel O Day and Dr. Linda Higgins as non-independent directors of Galapagos and the approval of the issuance of two warrants for the

benefit of Gilead Therapeutics A1 Unlimited Company.

All documents relating to the shareholders meetings will be posted on our website at

https://www.glpg.com/shareholders-meetings.

Conference call and webcast presentation

Galapagos will conduct a conference call open to the public tomorrow, 25 October at 14:00 CET / 8 AM ET, which will also be webcast. To participate in the

conference call, please call one of the following numbers ten minutes prior to commencement:

A question and answer session will follow the presentation of the results. Go to www.glpg.com to access the live audio

webcast. The archived webcast will also be available for replay shortly after the close of the call.

20 February 2020 Full year 2019 results (webcast 21 February 2020)

Filgotinib and all other drug candidates mentioned in this report are investigational; their efficacy and safety have not been fully evaluated by any

regulatory authority.

(Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises

Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative

medicines. More information at www.glpg.com.

VP Investor Relations

Senior Director Communications & Public

Director Communications

Forward-looking statements

This release may contain forward-looking statements, including, among other things, statements regarding the global R&D collaboration with Gilead, the

amount and timing of potential future milestone, opt-in and/or royalty payments by Gilead, Galapagos strategic R&D ambitions, the guidance from management (including guidance regarding the expected

operational cash burn during financial year 2019), financial results, timing and/or results of clinical trials, mechanisms of action and potential commercialization of our product candidates, interaction with regulators, and build-up and development of commercial operations. Galapagos cautions the reader that forward-looking statements are not guarantees of future performance. Forward-looking statements involve known and unknown risks,

uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial

conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Galapagos results, performance, financial condition and liquidity, and the development of the industry in which

it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that Galapagos expectations regarding its 2019

operating expenses may be incorrect (including because one or more of its assumptions underlying its expense expectations may not be realized), Galapagos expectations regarding its development programs may be incorrect, the inherent

uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from Galapagos ongoing clinical research programs may not support registration

or further development of its product candidates due to safety, efficacy or other reasons), Galapagos reliance on collaborations with third parties (including our collaboration partner for filgotinib, Gilead, our collaboration partner for

GLPG1972, Servier and our collaboration partners for MOR106, Novartis and MorphoSys), and estimating the commercial potential of its development programs. A further list and description of these risks, uncertainties and other risks can be found in

Galapagos Securities and Exchange Commission (SEC) filings and reports, including in Galapagos most recent annual report on Form 20-F filed with the SEC and other filings and reports filed by

Galapagos with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos

expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based

or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

This alternative performance

measure is in our view an important metric for a biotech company in the development stage.